長江生命科技:二零二三年年報
Changes in Hong Kong stocks | Changjiang Life Technology (00775) rises by nearly 30%. The company will display cancer vaccine research data and cancer vaccine model research cooperation data
Changjiang Life Science (00775) rose by nearly 30%. As of press release, it rose 21.88% to HK$0.39, with a turnover of HK$13.1371 million.
Changes in Hong Kong stocks | Changjiang Life Technology (00775) rose 20% in the afternoon to present cancer vaccine model research cooperation data at the AACR annual meeting
The Zhitong Finance App learned that Changjiang Life Technology (00775) rose 20% in the afternoon. As of press release, it had risen 9.68% to HK$0.34, with a turnover of HK$5.9977 million. According to the news, Changjiang Life Science announced in the afternoon that, together with partner XtalPi (XtalPi), it will show how its artificial intelligence driven (AI) platform can be applied to design cancer vaccines at the American Association for Cancer Research (AACR) 2024 Annual Meeting to be held in San Diego, USA. The two sides discovered that the AI model developed in the research collaboration can significantly improve the design of novel antigen peptide vaccines. In advance
Changjiang Life Science (00775.HK): New data from preclinical research on KRAS and PD-L1 research cancer vaccines will be exhibited at the AACR 2024 annual meeting
Gelonghui, April 5, 丨 Changjiang Life Technology (00775.HK) announced that the company will present two sets of new pre-clinical research data on rat sarcoma virus oncogene (KRAS) and cell-mediated death-ligand 1 (PD-L1) research cancer vaccines at the 2024 annual meeting of the American Association for Cancer Research (AACR) to be held in San Diego, California, USA. According to the disclosure, KRAS protein is commonly mutated in various cancers and is a key regulator of cell growth and survival, driving tumor growth by promoting uncontrolled cell reproduction and resistance to treatment. PD-L1 protein is
Investors Don't See Light At End Of CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Tunnel And Push Stock Down 26%
Unfortunately for some shareholders, the CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) share price has dived 26% in the last thirty days, prolonging recent pain. Instead of being rewarded, sha
Changjiang Life Science (00775.HK): Profit attributable to shareholders in 2023 HK$17.25 million
Gelonghui, March 19, 丨 Changjiang Life Technology (00775.HK) announced that for the year ended December 31, 2023, it achieved revenue of HK$5.323 billion, up 1% year on year; recorded profit attributable to shareholders of HK$17.25 million, down 87% year on year, with a basic profit of 0.18 cents per share. The business environment has been turbulent for the past three years. In 2021, as the coronavirus epidemic began to recede, the company promptly raised prices, streamlined operations and improved efficiency to mitigate the impact of inflation, labor shortages and supply chain disruptions. When central banks around the world raised interest rates sharply in 2022 to curb inflation
CKLIFE SCIENCES: ANNUAL RESULTS FOR 2023
Changjiang Life Science (00775.HK) held a board meeting on March 19 to approve publication of annual results
Gelonghui, March 7, 丨 Changjiang Life Technology (00775.HK) announced that the company will hold a board meeting in Hong Kong on March 19, 2024 (Tuesday) to (among others) approve the publication of the results of the company and its subsidiaries for the financial year ended 31 December 2023 and consider payment of a final dividend.
Changjiang Life Science (00775.HK) expects profit attributable to shareholders for the year to be drastically reduced
Gelonghui, Feb. 21丨Changjiang Life Technology (00775.HK) announced that the company expects profit attributable to shareholders for the year ended December 31, 2023 to be drastically reduced compared to the previous year. This reduction is expected to exceed those reported by the company in its 2023 interim report and is due to the impact of a sharp increase in financial costs on the Group's overall profit in the reporting year. The Group's operations remained stable during the reporting year and as of the date of this announcement.
CKLIFE SCIENCES: INSIDE INFORMATION ANNOUNCEMENT
The Three-year Underlying Earnings Growth at CK Life Sciences Int'l. (Holdings) (HKG:775) Is Promising, but the Shareholders Are Still in the Red Over That Time
You can invest in an index fund if you want to make sure your returns approximately match the overall market. But in any given year a good portion of stocks will fall short of that. Unfortunately fo
Is CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) ROE Of 2.5% Concerning?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to
Changjiang Life Technology (00775.HK) will present pre-clinical research data on PRAME and PD-L1 double antigen cancer vaccines at the annual meeting of the Society of Cancer Immunotherapy
Gelonghui November 1 | Changjiang Life Technology (00775.HK) announced that the company will present pre-clinical research data on the development of a dual antigen cancer vaccine targeting melanoma priority antigen (PRAME) and cytostatic death-ligand 1 (PD-L1) at the annual meeting of the Society of Cancer Immunotherapy to be held in San Diego, California, USA on November 4, 2023. The cancer vaccine in this preclinical study contains PRAME and PD-L1 antigen sequences to induce an anti-cancer immune response. PRAME is a cancer antigen commonly found in many different types of cancer, and various carcinogens
Despite Lower Earnings Than Five Years Ago, CK Life Sciences Int'l. (Holdings) (HKG:775) Investors Are up 57% Since Then
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) shareholders might be concerned after seeing the share price drop 14% in the last quarter. Looking further back, the stock has generated good prof
CK Life Sciences International's Profit Slumps 43% in H1; Shares Down 3%
CK Life Sciences International (Holdings) (HKG:0775) booked a profit attributable to shareholders of HK$36.9 million for the first half, slumping 43% from HK$65.1 million in the prior year. Earnings p
CKLIFE SCIENCES: Interim Report 2023
Changes in Hong Kong stocks | Changjiang Life Technology (00775) fell more than 5%, medium-term return profit fell 43.32% year on year
The Zhitong Finance App learned that Changjiang Life Technology (00775) fell more than 5%. As of press release, it fell 3.8% to HK$0.76, with a turnover of HK$3.4895 million. According to the news, Changjiang Life Technology announced its 2023 interim results yesterday, with revenue of about HK$2,579 billion, up 1.52% year on year; profit attributable to shareholders of HK$369.12 million, down 43.32% year on year; profit of HK0.38 cents per share. The announcement said that the overall profit for the first half of 2023 was heavily pressured by high financial costs caused by interest rate hikes.
CKLIFE SCIENCES: Announcement - Interim Results for 2023
Changjiang Life Technology (00775.HK) will hold a board meeting on August 1 to approve interim results
GLONGHUI, July 20, 丨Changjiang Life Technology (00775.HK) announced that the company will hold a board meeting on August 1, 2023 to approve the publication of the company and its subsidiaries's interim results for the six months ended June 30, 2023, and consider the payment of interim dividends.
CKLIFE SCIENCES: Date of Board Meeting
No Data